Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Reported and computed values remain separate; missing values are not converted to zero.
Research path: Interpret Sun Pharma Advanced Research Company Ltd's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Calculated from validated daily candles. Descriptive research only.
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
IND AS · INR crore
Overall RiskHigh risk
Board Risk63.76
Only peers present in the company profile payload are displayed.
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Not available
Sun Pharma Advanced Research Company Ltd has the symbol SPARC and ISIN - INE232I01014.
Sun Pharma Advanced Research Company Ltd is currently trading at INR 185.15.
Sun Pharma Advanced Research Company Ltd has a year high of INR 289.00 and a year low of INR 108.00.
Sun Pharma Advanced Research Company Ltd has a market capitalization of INR 7,017.91 crore.
Sun Pharma Advanced Research Company Ltd has a P/E ratio of NA.
Sun Pharma Advanced Research Company Ltd has a dividend yield of NA.
Sun Pharma Advanced Research Company Ltd has revenue of NA, net income of NA, and EPS of NA.
Sun Pharma Advanced Research Company Ltd has a book value of NA.
Sun Pharma Advanced Research Company Ltd has a debt-to-equity ratio of NA.
Sun Pharma Advanced Research Company Ltd has a price-to-book ratio of NA and a price-to-sales ratio of NA.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.